Industries > Pharma > Global Diabetes Drugs Market 2017-2027

Global Diabetes Drugs Market 2017-2027

Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others

PUBLISHED: 27 July 2017
PAGES: 262
PRODUCT CODE: PHA0218
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0218 Categories: , Tag:

The global diabetes drugs market was valued at $49.26bn in 2016 and is projected to grow at a CAGR of 6.1% in the first half of the forecast period.to reach global revenue of $66.29bn in 2021. The largest drug class in the market in 2016 was human insulin and analogues. This drug class held 55% share of the global diabetes drugs market in 2016.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 262 page report you will receive 75 tables and 141 figures – all unavailable elsewhere.

The 262-page report provides clear detailed insight into the global diabetes drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Diabetes Drugs Market forecasts from 2017-2027

• Provides qualitative analysis and forecast of the human insulins and analogues submarket for the period 2017-2027:
• Lantus (insulin aspart)
• NovoLog (insulin aspart)
• Humalog (insulin lispro)
• Levemir (insulin detemir)
• Human Insulins by Novo Nordisk
• NovoMix (insulin aspart)
• Humulin (insulin isophane)

• Provides qualitative analysis and forecast of the dipeptidyl peptidase-4 inhibitors (DPP-4) submarket for the period 2017-2027:
• Januvia (sitagliptin)
• Janumet (sitagliptin and metformin)
• Galvus (vidagliptin)
• Onglyza (saxagluiptin)
• Nesina (alogliptin)
• Tradjenta (linagliptin)

• Provides qualitative analysis and forecast of the sulfonylurea submarket for the period 2017-2027:
• Diamicron (gliclazide)
• Amaryl (glimepiride)
• Glucotrol (glipizide)

• Provides qualitative analysis and forecast of the glucagon-like peptide-1 (GLP-1) receptor agonists submarket for the period 2017-2027:
• Victoza (liraglutide)
• Byetta (exenatide)
• Bydureon (exenatide)

• Provides qualitative analysis and forecast of the alpha-glucosidase class submarket for the period 2017-2027:
• Glucobay (acarbose)
• Basen (voglibose)
• Glyset (miglitol)

Global Diabetes Drugs Market 2017-2027

• Provides qualitative analysis and forecast of the meglitinides submarket for the period 2017-2027:

• Prandin (repaglinide)
• Sarlix (nateglinide)
• Glufast (acarbose).

• Provides qualitative analysis and forecast of the sodium-glucose co-transporter 2 (SGLT2) inhibitors submarket for the period 2017-2027:
• Invokana (canagliflozin)
• Forxiga (dapagliflozin)
• Jardiance (empaglifozin)

• Provides qualitative analysis and forecast of the biguanides submarket for the period 2017-2027:
• Glucophage (metformin)
• Glumetza (metformin)
• Fortamet (metformin)

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• United States
• Japan
• EU5 (Germany, France, UK, Italy, Spain)
• China
• India
• Russia
• Brazil

• This report discusses the SWOT and STEP Analysis of the global diabetes drugs market

• This report also discusses the diabetes R&D pipeline, recent approvals and summarizes anti-diabetes drug developments by Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca and others

Visiongain’s study is intended for anyone requiring commercial analyses for the global diabetes drugs market. You find data, trends and predictions.

Buy our report today Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Diabetes Drugs Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Diabetes Drugs Market 2017-2027


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category